RETIN-A GEL Rx
Generic Name and Formulations:
Tretinoin 0.01%, 0.025%; alcohol 90%.
Valeant Pharmaceuticals, Inc
Indications for RETIN-A GEL:
Apply sparingly at bedtime to clean dry skin; adjust strength and frequency as tolerated and needed.
Not for use in eczema or sunburned skin. Avoid eyes, mouth, angles of nose, mucous membranes, sun, UV light. Discontinue if sensitivity reactions occur. Increased irritation in weather extremes. Gel: flammable. Pregnancy (Cat.C): not recommended. Nursing mothers.
Caution with concomitant topical medication, medicated or abrasive soaps/cleansers, astringents, drying agents, high-alcohol content topical products, spices. Avoid contact with peel of limes. Allow effects of benzoyl peroxide, sulfur, resorcinol, salicylic acid, other topical acne agents to subside before applying.
Local irritation, skin pain, pruritus, pharyngitis, erythema, transient symptom exacerbation or pigmentation changes, dryness, stinging, photosensitivity.
Micro 0.04%, 0.1%—20g, 45g, 50g; 0.08%—50g; Crm—20g, 45g; Gel—15g, 45g; Liq—28mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|